In a report released on February 7, Kevin Heal from Argus Research maintained a Buy rating on Raymond James Financial (RJF – Research Report).
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The next CEO of Raymond James talks about how private equity ownership has made for some difficult marriages in wealth ...
In a report released today, Stephen Boland from Raymond James maintained a Buy rating on Intact Financial Corporation (IFC – Research Report), ...
Raymond James is seeing a beneficial shift to advisory as well as recovering M&A activity, which may continue. Read why I ...
James reiterated its Strong Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS), with a price target of $78.00. The stock, currently trading at $28.51, shows significant upside potential according to ...
LPL Financial welcomes a $345 million investment and planning team from Ameriprise as RayJay's employee advisor arm adds a ...
In earnings calls, both Raymond James and Ameriprise cited strong recruiting pipelines as they beat analysts’ income ...
Stock analysts at Seaport Res Ptn raised their Q3 2025 earnings per share estimates for Raymond James in a report released on ...